EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis

Michael Youssef iD, Kelly Dong, So Jeong Lee, Neeraj Narula

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad013 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Michael Youssef und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Aminosalicylic Acid, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High histologic remission rates have been reported with placebos in randomized controlled trials (RCTs) evaluating ulcerative colitis (UC) therapies and have varied based on trial designs. We performed a systematic review and meta-analysis to quantify placebo histological remission rates and identify factors influencing those rates.

Methods

MEDLINE, EMBASE, and the Cochrane library were searched from inception of the databases until December 2021. We included placebo-controlled RCTs of adult patients with UC treated with aminosalicylates, corticosteroids, immunosuppressives, biologics, and small molecules. We pooled estimates using a random-effects model and performed subgroup analysis and meta-regression to evaluate the effect of different covariates on placebo rates.

Results

Thirty-three studies (30 induction and 3 maintenance) were included. The overall placebo histological remission rate was 15.7% (95% confidence interval, 12.9%-19%) across all 33 studies. High heterogeneity was observed among studies with I2 = 62.10%. The pooled estimate of histological remission was 15.8% in induction studies and 14.5% in maintenance studies. Subgroup analysis revealed statistically significant differences in placebo rates when accounting for background medications, the intervention drug class, and disease severity (P = .041, .025, and .025, respectively). There was no statistical difference between induction vs maintenance studies or between different histological scales (P = .771, and .075, respectively).

Conclusions

Placebo histological remission rates range from 13% to 19% in UC RCTs, but studies are highly heterogeneous. Factors found to influence placebo rates include presence of background medications, the drug used, and the disease severity. These observations inform future trial designs to minimize placebo rates and reduce heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAminosalicylic AcidBiological ProductsAdultHumansImmunosuppressive AgentsRemission Induction

Stichwörter der Autor:innen

histological remissionplacebo ratesrandomized control trialsulcerative colitis

Substanzen

Immunosuppressive AgentsAminosalicylic AcidBiological Products

Autor:innen und Institutionen

  • Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Department of General Surgery, McMaster University, Hamilton, ON, Canada.
  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.

ORCID-Profile: Michael Youssef

Zitieren

APA

Youssef, M., Dong, K., Lee, S. J., & Narula, N. (2024). Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad013

Vancouver

Youssef M, Dong K, Lee SJ, Narula N. Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad013

BibTeX
@article{Youssef2024,
  author = {Youssef, Michael and Dong, Kelly and Lee, So Jeong and Narula, Neeraj},
  title = {Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad013}
}
Kostenlos starten →